Deals
Amgen Said to Boost Bid for Onyx Pharma to $130 a Share
This article is for subscribers only.
Amgen Inc., the drugmaker in pursuit of Onyx Pharmaceuticals Inc., boosted its offer for the company to $130 a share, according to a person familiar with the matter.
The bid is currently the highest for Onyx, said the person, who asked not to be named because the process is private. If none of the other companies that have expressed interest beat Amgen’s proposal, a deal could be done by the end of this week, the person said.